Evidence map›Paper›PMID 39896512›Full record

ArticlebioRxiv : the preprint server for biology2025

Spatial profiling identifies regionally distinct microenvironments and targetable immunosuppressive mechanisms in pediatric osteosarcoma pulmonary metastases.

Jason Eigenbrood, Nathan Wong, Paul Mallory, Janice Pereira, Douglass W Morris-Ii, Jessica A Beck, James C Cronk, Carly M Sayers, Monica Mendez, Linus Kaiser and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jason EigenbroodPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Nathan WongCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Paul MalloryImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Janice PereiraPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Douglass W Morris-IiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jessica A BeckComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
James C CronkPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Carly M SayersPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Monica MendezDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Linus KaiserDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Julie GalindoDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Jatinder SinghCenter for Cancer Research Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, MD, USA.
Ashley CardamoneImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Milind PoreImaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Michael KellyCenter for Cancer Research Single Cell Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory, Bethesda, MD, USA.
Amy K LeBlancComparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jennifer CotterDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Rosandra N KaplanPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Troy A McEachronPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Identification of immune evasion mechanisms in the osteosarcoma microenvironmentZIABC012056 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCEACHRON, TROY · 2021 to 2025
$6.4M
Intramural NIH HHS ZIA BC012056NCI NIH HHS 75N91019D00024NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Osteosarcoma is the most common malignant bone tumor in young patients and remains a significant clinical challenge, particularly in the context of metastatic disease. Despite extensive documentation of genomic alterations in osteosarcoma, studies detailing the immunosuppressive mechanisms within the metastatic osteosarcoma microenvironment are lacking. Our objective was to characterize the spatial transcriptional landscape of metastatic osteosarcoma to reveal these immunosuppressive mechanisms and identify promising therapeutic targets. Here, we performed spatial transcriptional profiling on a cohort of osteosarcoma pulmonary metastases from pediatric patients. We reveal a conserved spatial gene expression pattern resembling a foreign body granuloma, characterized by peripheral inflammatory signaling, fibrocollagenous encapsulation, lymphocyte exclusion, and peritumoral macrophage accumulation. We also show that the intratumoral microenvironment of these lesions lack inflammatory signaling. Additionally, we identified CXCR4 as an actionable immunomodulatory target that bridges both the intratumoral and extratumoral microenvironments and highlights the spatial heterogeneity and complexity of this pathway. Collectively, this study reveals that metastatic osteosarcoma specimens are comprised of multiple regionally distinct immunosuppressive microenvironments.

Identifiers

PMID39896512
PMCPMC11785069

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.